Fairmount Funds Management LLC Protagonist Therapeutics, Inc Transaction History

Fairmount Funds Management LLC

  • $615 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$21.79 - $32.15 $20.3 Million - $30 Million
931,890 New
931,890 $27 Million
Q2 2022

Aug 15, 2022
SELL
$7.06 - $25.52 $3.88 Million - $14 Million
-549,988 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$23.34 - $36.08 $12.8 Million - $19.8 Million
549,988 New
549,988 $13 Million

Others Institutions Holding PTGX

# of Institutions
248
Shares Held
56.7M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Fairmount Funds Management LLC Portfolio

Follow Fairmount Funds Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fairmount Funds Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email